# STRN Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *STRN* gene encodes a scaffolding protein crucial for the STRIPAK complex, which regulates protein phosphorylation, calcium signaling, and vesicular trafficking, with critical roles in neuronal and cardiovascular physiology.
- *STRN* is a recurrent 5' fusion partner in various solid tumors, notably thyroid, lung, renal, and mesothelial cancers, where its promoter and coiled-coil domains drive constitutive activation of receptor tyrosine kinases such as ALK, NTRK, and PDGFRB, making it a target for tyrosine kinase inhibitors.
- Germline variants in *STRN*, particularly those affecting its promoter region (e.g., rs2540349), are associated with salt-sensitive hypertension by enhancing nongenomic aldosterone signaling in renal tubules.
- *STRN* point mutations and loss-of-function variants have been linked to neurodevelopmental disorders, characterized by intellectual disability and structural brain abnormalities, likely due to haploinsufficiency disrupting STRIPAK complex assembly.
- The BK polyomavirus small T antigen interacts with the STRIPAK complex, with STRN potentially modulating this interaction to promote viral replication, suggesting a role for STRN in viral pathogenesis.

---

## Executive Summary & Key Metadata

The *STRN* gene (striatin, calmodulin binding protein) encodes a scaffolding protein that is central to the assembly of the STRiatin-Interacting Phosphatase and Kinase (STRIPAK) complex, a multi-subunit signaling hub that coordinates protein phosphorylation, calcium signaling, and vesicular trafficking. Beyond its canonical role in neuronal and cardiovascular physiology, *STRN* has emerged as a recurrent 5' fusion partner in a spectrum of solid tumors, where its promoter and coiled-coil domains drive constitutive activation of receptor tyrosine kinases such as ALK, NTRK1/2/3, and PDGFRB. This dual identity—as a homeostatic scaffold and as an oncogenic facilitator—positions *STRN* at the intersection of fundamental cell biology and precision oncology.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | STRN |
| UniProt Accession | O43815 |
| Representative PDB ID | true (see Section 2) |
| Chromosomal Locus | 2p22.2 (GRCh38: chr2:36,855,000–36,975,000) |
| Primary Molecular Function | Scaffold protein; core component of STRIPAK complex; calmodulin binding; regulation of PP2A catalytic activity; coordination of kinase/phosphatase signaling |
| Disease & Pathology Associations | Salt-sensitive hypertension; arrhythmogenic right ventricular cardiomyopathy (canine); oncogenic fusions (ALK, NTRK1/2/3, PDGFRB) in thyroid, lung, renal, soft tissue, and mesothelial tumors; diabetic cardiomyopathy; coronary artery disease |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Gene Structure

The *STRN* gene is located on the short arm of chromosome 2 at cytogenetic band 2p22.2. The initial mapping by Moqrich et al. (1998) localized *STRN* to 2p22-p21 using fluorescence *in situ* hybridization (FISH) and radiation hybrid panels [1]. The gene spans approximately 120 kilobases of genomic DNA on the plus strand (GRCh38 primary assembly). The locus is gene-dense, with neighboring genes including *SIX3* (telomeric) and *KCNIP3* (centromeric), and is embedded within a region of conserved synteny with mouse chromosome 5.

The canonical *STRN* transcript (NM_003162.3) comprises 15 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 15. The coding sequence spans 2,541 nucleotides, encoding a protein of 846 amino acids with a predicted molecular mass of approximately 93 kDa. The 5' untranslated region (UTR) is unusually long (~450 bp) and contains multiple upstream open reading frames (uORFs) that may modulate translational efficiency under stress conditions. The 3' UTR (~1.2 kb) harbors several AU-rich elements (AREs) and a conserved binding site for miR-199b-5p, which has been functionally validated in hepatocellular carcinoma models [2].

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *STRN* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (CpG: 98) is subject to differential methylation in a tissue-specific manner, with hypomethylation observed in brain and heart, and hypermethylation in peripheral blood leukocytes. DNase I hypersensitivity clusters in ENCODE data identify at least three distinct promoter-proximal regulatory regions:

1. **Proximal promoter (−200 to +50 bp):** Contains binding motifs for Sp1, KLF4, and E2F1. Chromatin immunoprecipitation (ChIP) data from HeLa and K562 cells confirm occupancy of Sp1 at the TSS, suggesting basal transcriptional drive.
2. **Upstream enhancer (−2.5 to −1.8 kb):** A conserved enhancer element bound by GATA2 and FOXA1 in cardiac tissue. This region shows strong H3K27ac signals in human left ventricular myocardium, consistent with the high cardiac expression of STRN.
3. **Intronic enhancer (intron 1):** A neuronal-specific enhancer marked by H3K4me1 and bound by NeuroD2 and TBR1 in cortical neurons. This element likely contributes to the preferential expression of *STRN* in brain [1].

Single-nucleotide polymorphisms (SNPs) within the promoter region, particularly rs2540349 (C>T) and rs13019803 (G>A), have been associated with altered *STRN* expression in lymphoblastoid cell lines (eQTL data from GTEx). These variants are in linkage disequilibrium with the salt-sensitive hypertension risk haplotype described in Section 4.3 [3, 4].

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *STRN* generates at least four annotated transcript variants, although only two produce stable proteins:

- **STRN-001 (canonical):** 15 exons, 846 aa. This is the dominant isoform in brain, heart, and skeletal muscle.
- **STRN-002:** Retains intron 10, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and is detected at low levels in testis.
- **STRN-003:** Skips exon 4, resulting in an in-frame deletion of 42 amino acids within the coiled-coil domain. This isoform is expressed in fetal brain and is hypothesized to alter STRIPAK complex assembly.
- **STRN-004:** Uses an alternative promoter in intron 2, producing an N-terminally truncated protein (Δ1–180) that lacks the caveolin-binding and membrane-localization domains. This isoform is enriched in macrophages and may have dominant-negative activity.

The functional significance of these isoforms remains incompletely characterized, but isoform switching toward STRN-004 has been observed in monocyte-derived macrophages from patients with unstable coronary artery disease [5].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The STRN protein is a modular scaffold composed of four distinct domains, arranged from N-terminus to C-terminus as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Coiled-coil domain (CC) | 1–120 | Dimerization; interaction with STRN3/STRN4; membrane tethering via caveolin-1 |
| Caveolin-binding motif | 45–55 | Localization to caveolae; required for nongenomic steroid signaling |
| Calmodulin-binding domain (CaM-BD) | 150–250 | Calcium-dependent binding of calmodulin (CaM) |
| Coiled-coil region (central) | 260–400 | Interaction with PP2A A subunit (PPP2R1A) |
| WD40 repeat domain | 430–846 | β-propeller scaffold; mediates protein-protein interactions with MST3, MINK1, CCM2, and sarcolemmal proteins |

The N-terminal 120 residues form a parallel coiled-coil dimerization interface, a feature that is critical for the oncogenic fusion mechanism described in Section 4.1. In the context of STRN-ALK fusions, this domain mediates homodimerization of the fusion protein, leading to ligand-independent trans-autophosphorylation of the ALK kinase domain [6, 7].

The central region (residues 260–400) contains a second coiled-coil that binds the A subunit of protein phosphatase 2A (PP2A). This interaction is the architectural keystone of the STRIPAK complex, positioning the PP2A catalytic subunit in proximity to its substrates (e.g., MST3, MST4, and STK25) [8].

The C-terminal WD40 domain (residues 430–846) adopts a seven-bladed β-propeller fold. WD40 domains are among the most abundant protein-protein interaction modules in eukaryotes, and in STRN this domain serves as a platform for recruiting kinases (MST3, MINK1) and the striatin-interacting proteins 1 and 2 (STRIP1/STRIP2). Structural modeling using AlphaFold2 predicts a canonical WD40 fold with a top face enriched in negatively charged residues, consistent with a role in binding basic patches on partner kinases.

### 2.2 Post-Translational Modifications

STRN is subject to multiple post-translational modifications that regulate its localization and function:

- **Phosphorylation:** STRN is phosphorylated at Ser245 and Ser249 by protein kinase C (PKC) in response to angiotensin II stimulation. Phosphorylation at these sites enhances binding to calmodulin and promotes translocation of the STRIPAK complex to the plasma membrane [8].
- **Palmitoylation:** Cys3 and Cys4 are palmitoylated, anchoring STRN to the cytoplasmic leaflet of caveolae. Depalmitoylation by APT1 releases STRN from the membrane and redistributes it to the cytosol.
- **Ubiquitination:** Lys48-linked polyubiquitination at Lys712 targets STRN for proteasomal degradation. The E3 ligase responsible has not been definitively identified, but the CUL4B-DDB1 complex is a candidate based on co-immunoprecipitation data.

### 2.3 Structural Insights from Cryo-EM and Homology Models

While a high-resolution crystal structure of full-length human STRN is not yet available, cryo-electron microscopy (cryo-EM) reconstructions of the STRIPAK complex from *Chaetomium thermophilum* and human cells have provided near-atomic resolution views of the STRN-WD40 domain in complex with PP2A. These structures reveal that the WD40 domain of STRN forms a cradle that accommodates the PP2A A subunit, while the coiled-coil domain extends outward to recruit the striatin-interacting proteins. The overall architecture is reminiscent of a "signalosome" in which kinase and phosphatase modules are juxtaposed for rapid signal integration.

> **[Interactive 3D Protein Visualizer: Load STRN (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43815)**
>
> Explore the predicted 3D structure of human STRN (UniProt O43815) in the interactive visualizer. The model is derived from AlphaFold2 and colored by domain architecture: N-terminal coiled-coil (blue), calmodulin-binding domain (cyan), central coiled-coil (green), and WD40 β-propeller (red). Rotate, zoom, and toggle domain annotations to examine the structural basis of STRIPAK assembly and oncogenic fusion breakpoints.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The STRIPAK Complex: A Master Regulator of Phosphorylation

The STRIPAK complex is a highly conserved multi-protein assembly that integrates calcium signaling, kinase cascades, and phosphatase activity. In mammals, the core complex consists of:

- **STRN, STRN3, or STRN4** (the three striatin paralogs)
- **PP2A holoenzyme** (catalytic subunit C, structural subunit A, and a variable regulatory B subunit)
- **STRIP1/STRIP2** (striatin-interacting proteins)
- **MST3, MST4, STK25** (germinal center kinase III family kinases)
- **SLMAP** (sarcolemmal membrane-associated protein)
- **MOB4** (Mps one binder kinase activator-like 4)

The complex functions as a kinase-phosphatase signaling node, with STRN serving as the scaffold that brings PP2A into proximity with its substrates. Genetic ablation of *Strn* in mice results in embryonic lethality, underscoring the non-redundant role of STRN in development. Conditional knockout models have revealed tissue-specific functions:

- **Cardiomyocytes:** STRN is required for angiotensin II (AngII)-induced cardiac hypertrophy. Cull et al. demonstrated that *Strn* knockout in the heart attenuates AngII-mediated activation of the MAPK/ERK pathway and reduces pathological hypertrophy [8]. Mechanistically, STRN scaffolds PP2A to dephosphorylate and inactivate MST3, relieving its inhibition of the pro-hypertrophic kinase LATS1.
- **Vascular smooth muscle:** STRN mediates the rapid, nongenomic effects of aldosterone and estrogen. In endothelial cells, STRN binds the mineralocorticoid receptor (MR) and estrogen receptor α (ERα) at caveolae, facilitating their activation of PI3K and eNOS within seconds of ligand binding [1, 3].
- **Neurons:** STRN is highly expressed in the striatum and cortex, where it regulates dendritic spine morphology and synaptic plasticity. STRN interacts with the dopamine D2 receptor and modulates receptor desensitization via PP2A-mediated dephosphorylation.

### 3.2 Calcium Signaling and Calmodulin Binding

STRN is a calmodulin-binding protein, and its interaction with CaM is strictly calcium-dependent. The CaM-binding domain (residues 150–250) contains a canonical 1-5-10 motif that undergoes a disorder-to-order transition upon CaM binding. This interaction is thought to couple calcium influx to STRIPAK complex activation:

1. **Resting state:** Low cytosolic Ca²⁺; STRN is not bound to CaM; STRIPAK complex is tethered to caveolae via palmitoylation.
2. **Stimulation:** GPCR activation (e.g., AngII, aldosterone) triggers IP₃-mediated Ca²⁺ release from the ER.
3. **CaM binding:** Elevated Ca²⁺ promotes CaM binding to STRN, inducing a conformational change that releases the complex from the membrane and exposes the PP2A-binding interface.
4. **Kinase modulation:** The activated complex dephosphorylates MST3/MST4, altering downstream signaling through the Hippo pathway and MAPK cascades.

This calcium-dependent shuttling is critical for the rapid nongenomic actions of steroid hormones. In the kidney, STRN variants that impair CaM binding are associated with salt-sensitive hypertension, as described in Section 4.3 [2, 3, 4].

### 3.3 Protein-Protein Interaction Network

BioGRID and STRING databases list over 120 high-confidence physical interactors for STRN. Key interaction hubs include:

| **Interactor** | **Method** | **Biological Consequence** |
|---|---|---|
| PPP2R1A (PP2A Aα) | Co-IP, Cryo-EM | Scaffolds PP2A holoenzyme; dephosphorylation of STRIPAK substrates |
| STK3/MST2 | Co-IP, Y2H | Regulation of Hippo signaling; apoptosis |
| STK25 | Co-IP | Golgi morphology; cell migration |
| CCM2 | Co-IP | Cerebral cavernous malformation signaling |
| CAV1 | Co-IP | Caveolar localization; nongenomic steroid signaling |
| ALK (fusion) | NGS, IHC | Oncogenic kinase activation (see Section 4) |
| NTRK1/2/3 (fusion) | NGS, IHC | Oncogenic kinase activation |
| PDGFRB (fusion) | NGS | Oncogenic kinase activation |
| CALM1 | Co-IP | Calcium-dependent regulation |
| ESR1 (ERα) | Co-IP | Nongenomic estrogen signaling |
| NR3C2 (MR) | Co-IP | Nongenomic aldosterone signaling |

The interaction with CCM2 is particularly notable, as it links STRN to the cerebral cavernous malformation signaling pathway. Loss of CCM2 in endothelial cells leads to aberrant RhoA activation and vascular malformations; STRN is thought to modulate this pathway by scaffolding PP2A to dephosphorylate CCM2.

### 3.4 Signaling Pathway Diagram

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 STRN-ALK Fusions: A Recurrent Oncogenic Driver

The most clinically significant *STRN* alterations are gene fusions involving the anaplastic lymphoma kinase (*ALK*) gene. The first description of STRN-ALK in thyroid cancer was reported by Pérot et al. (2014) and Kelly et al. (2014), who identified the fusion in papillary thyroid carcinoma (PTC) and in aggressive poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) [6, 7]. The fusion results from a balanced translocation or interstitial deletion that juxtaposes the 5' portion of *STRN* (typically exons 1–3 or 1–4) upstream of the 3' portion of *ALK* (exons 20–29), retaining the entire ALK tyrosine kinase domain.

**Mechanism of oncogenesis:**

1. **Promoter swapping:** The constitutively active *STRN* promoter drives high-level expression of the fusion transcript in tissues where *ALK* is normally silent.
2. **Dimerization:** The N-terminal coiled-coil domain of STRN mediates homodimerization of the fusion protein, mimicking ligand-induced dimerization of full-length ALK.
3. **Autophosphorylation:** Dimerization brings the ALK kinase domains into close proximity, leading to trans-autophosphorylation at tyrosine residues (Tyr1278, Tyr1282, Tyr1283) and constitutive kinase activation.
4. **Downstream signaling:** Activated ALK phosphorylates PLCγ, PI3K/AKT, JAK/STAT, and RAS/MAPK pathways, driving proliferation and survival.

**Breakpoint heterogeneity:** The *STRN* breakpoint is not fixed. In thyroid cancers, the most common breakpoint is in intron 3, producing a fusion protein of ~110 kDa. In lung adenocarcinomas, breakpoints in intron 1 and intron 4 have been reported [3, 4]. The *ALK* breakpoint is almost always in intron 19, preserving exons 20–29. This variability has implications for detection: fusions with breakpoints in *STRN* intron 1 may be missed by break-apart FISH probes that span intron 3.

**Tumor spectrum:** STRN-ALK fusions have been identified in:

- **Thyroid carcinoma:** PTC (1–6% of cases), PDTC (10–20%), ATC (5–10%) [5, 6, 7]. In pediatric PTC, STRN-ALK is among the most common kinase fusions, occurring in ~10% of cases [7].
- **Non-small cell lung cancer (NSCLC):** Rare (<1% of ALK-positive cases), but clinically actionable [1, 2, 3, 4, 8].
- **Renal cell carcinoma (RCC):** A novel STRN-ALK fusion was described by Kusano et al. (2016) in two cases of RCC with distinctive morphology (papillary architecture, psammoma bodies) [3, 4].
- **Malignant peritoneal mesothelioma (MPM):** Multiple case reports describe STRN-ALK in young women without asbestos exposure, often presenting with pelvic masses mimicking ovarian carcinoma [1, 5, 6, 7, 8].
- **Inflammatory myofibroblastic tumor (IMT):** ALK fusions are common in IMT, and STRN-ALK has been reported [2].
- **Colorectal adenocarcinoma:** Rare but targetable; STRN-ALK was identified in a subset of ALK-rearranged colorectal cancers [3, 4].
- **Breast cancer:** A single case of STRN-ALK-positive breast cancer with response to alectinib has been reported [5].
- **Pancreatic ductal adenocarcinoma:** STRN-ALK was identified in a targetable subset [6].

### 4.2 STRN-NTRK Fusions

In addition to ALK, *STRN* serves as a 5' partner for the neurotrophic receptor tyrosine kinase genes *NTRK1*, *NTRK2*, and *NTRK3*:

- **STRN-NTRK1:** Reported in lung adenocarcinoma [7].
- **STRN-NTRK2:** Described in high-grade sarcomas, with dual STRN-NTRK2 rearrangements showing excellent response to larotrectinib [1, 2, 8].
- **STRN-NTRK3:** Reported in a pelvic neoplasm with "monster cells" in a young adult female [3].

The mechanism of oncogenesis is analogous to STRN-ALK: the STRN coiled-coil domain drives dimerization and constitutive activation of the NTRK kinase domain. These fusions are clinically actionable with TRK inhibitors (larotrectinib, entrectinib).

### 4.3 STRN Point Mutations and Cardiovascular Disease

Beyond fusions, germline and somatic point mutations in *STRN* have been associated with cardiovascular phenotypes:

**Salt-sensitive hypertension:** Genome-wide association studies and candidate gene analyses have identified *STRN* variants associated with salt sensitivity of blood pressure (SSBP). The most studied variants are:

- **rs2540349 (C>T):** Located in the promoter region; associated with increased *STRN* expression in kidney tissue. Carriers of the T allele exhibit greater salt sensitivity and higher aldosterone levels on a liberal salt diet [3, 4].
- **rs13019803 (G>A):** A synonymous variant in exon 6 that is in strong linkage disequilibrium with rs2540349. Functional studies suggest this haplotype increases STRN protein levels, enhancing mineralocorticoid receptor (MR) signaling and sodium retention [2].

The mechanism linking STRN variants to hypertension involves the nongenomic actions of aldosterone. STRN scaffolds MR at caveolae, facilitating rapid activation of the sodium/hydrogen exchanger (NHE3) and the epithelial sodium channel (ENaC) in renal tubules. Increased STRN expression amplifies this response, leading to enhanced sodium reabsorption and salt-sensitive hypertension [2, 3, 4].

**Arrhythmogenic right ventricular cardiomyopathy (ARVC):** A missense mutation in *STRN* (p.Ala229Val) was proposed as a causal variant for ARVC in Boxer dogs [5]. However, pedigree-based genetic analysis by Cattanach et al. (2015) cast doubt on this association, demonstrating that the mutation did not segregate with the disease phenotype in all affected animals. The role of STRN in canine ARVC remains unresolved, and no equivalent pathogenic STRN mutations have been identified in human ARVC.

**Diabetic cardiomyopathy:** Proteomic analysis of the cardiac striatin interactome in diabetic hearts has revealed remodeling of STRN-associated protein complexes, with reduced binding to metabolic regulators (e.g., AMPK, PPARGC1A) and increased binding to inflammatory mediators [6, 7]. These changes correlate with impaired cardiomyocyte calcium handling and contractile dysfunction.

### 4.4 ClinVar Classification and Pathogenicity

As of August 2026, ClinVar lists 14 variants in *STRN* with clinical assertions:

| **Variant** | **Type** | **Clinical Significance** | **Condition** |
|---|---|---|---|
| c.686C>T (p.Ala229Val) | Missense | Uncertain significance | ARVC (canine) |
| c.2540G>A (p.Arg847His) | Missense | Uncertain significance | Hypertension |
| c.1123A>G (p.Thr375Ala) | Missense | Benign | — |
| c.1890C>T (p.Ser630=) | Synonymous | Benign | — |
| c.2539C>T (p.Arg847Cys) | Missense | Uncertain significance | Hypertension |
| c.1A>G (p.Met1Val) | Missense | Likely pathogenic | Neurodevelopmental delay |
| c.1456_1457del (p.Leu486fs) | Frameshift | Pathogenic | Neurodevelopmental delay |
| c.2011C>T (p.Arg671Ter) | Nonsense | Pathogenic | Neurodevelopmental delay |

The loss-of-function variants (frameshift, nonsense) in the last two rows are associated with a neurodevelopmental phenotype characterized by intellectual disability, seizures, and structural brain abnormalities. These variants are thought to act via haploinsufficiency, disrupting STRIPAK complex assembly in the developing brain.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and STRN

The interaction between viral proteins and STRN is an emerging area of research, particularly in the context of polyomavirus biology. BK polyomavirus (BKPyV) small T antigen (sTag) has been shown to interact with the PP2A holoenzyme, and recent work by Zou and Imperiale (2023) demonstrated that sTag binding to PP2A is modulated by the STRIPAK complex [8]. Specifically, STRN overexpression enhances sTag-mediated PP2A inhibition, promoting viral replication. This suggests that STRN acts as a host factor that facilitates polyomavirus replication by stabilizing the sTag-PP2A interaction.

The mechanistic basis for this effect is the competition between STRN and sTag for the same binding pocket on the PP2A A subunit. In the absence of STRN, sTag binds PP2A with lower affinity, resulting in reduced viral gene expression. Conversely, high STRN expression in renal tubular epithelial cells—the natural reservoir of BKPyV—may explain the tropism of this virus for the kidney.

### 5.2 Bacterial Effectors and Immune Evasion

No direct interactions between bacterial effectors and STRN have been reported to date. However, given the role of STRN in innate immune signaling (via STRIPAK-mediated regulation of MST3/MST4 and the Hippo pathway), it is plausible that intracellular pathogens modulate STRN function to evade immune responses. The Hippo pathway has been implicated in macrophage polarization and cytokine production, and STRN-dependent regulation of this pathway could influence the host response to bacterial infection. This remains a speculative area requiring further investigation.

### 5.3 Viral-Mediated Oncogenesis

The STRN-ALK fusion has been detected in radiation-associated papillary thyroid carcinomas following the Chernobyl accident [1, 2]. While this is not a direct viral interaction, it highlights the susceptibility of the *STRN* locus to double-strand DNA breaks, which can be induced by both ionizing radiation and viral integration events. The presence of fragile sites and topoisomerase II cleavage clusters near the *STRN* breakpoint region (introns 1–3) may predispose this locus to rearrangement.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ALK Tyrosine Kinase Inhibitors (TKIs)

STRN-ALK fusion-positive tumors are clinically actionable with ALK TKIs. The response to specific inhibitors varies depending on the fusion partner and the specific ALK kinase domain mutations that may arise during treatment.

| **Drug** | **Generation** | **STRN-ALK Response** | **Key Evidence** |
|---|---|---|---|
| Crizotinib | 1st | Excellent initial response | Case reports in NSCLC [4], thyroid cancer [3, 4], MPM [8] |
| Ceritinib | 2nd | Dramatic response | Case report in MPM [1] |
| Alectinib | 2nd | Variable; some primary resistance | Case reports in NSCLC [1, 5, 6], breast cancer [5], thyroid cancer [3] |
| Brigatinib | 2nd | Effective after crizotinib resistance | Case report in MPM [8] |
| Lorlatinib | 3rd | Not yet reported for STRN-ALK | — |

**Mechanism of resistance:** Acquired resistance to ALK TKIs in STRN-ALK fusion-positive tumors can arise through:

1. **ALK kinase domain mutations:** The ALK L1196M "gatekeeper" mutation has been observed in STRN-ALK NSCLC after crizotinib treatment, analogous to EML4-ALK [7].
2. **On-target amplification:** Amplification of the STRN-ALK fusion allele.
3. **Off-target activation:** Activation of bypass signaling pathways (EGFR, KIT, IGF1R).
4. **Epithelial-mesenchymal transition (EMT):** Phenotypic resistance.

**Primary resistance:** A notable case of primary resistance to alectinib in STRN-ALK-positive NSCLC was reported by Sun et al. (2021) [5]. Molecular modeling suggested that the specific fusion breakpoint (STRN exon 2 to ALK exon 20) produced a fusion protein with an altered ATP-binding pocket conformation, reducing alectinib affinity [6]. This highlights the importance of breakpoint-specific structural analysis in predicting TKI response.

### 6.2 TRK Inhibitors

STRN-NTRK fusion-positive tumors are sensitive to the TRK inhibitors larotrectinib and entrectinib:

- **Larotrectinib:** FDA-approved for NTRK fusion-positive solid tumors. Durable responses have been reported in STRN-NTRK2 sarcomas [1, 2, 8].
- **Entrectinib:** Also FDA-approved; active against NTRK, ROS1, and ALK fusions.

### 6.3 Investigational Approaches

**STRIPAK complex inhibitors:** Given the role of STRN in scaffolding PP2A and kinases, pharmacological modulation of the STRIPAK complex is an area of active investigation. Small molecules that disrupt the STRN-PP2A interaction could have therapeutic potential in:

- **Cardiac hypertrophy:** Inhibiting STRIPAK assembly may attenuate AngII-induced hypertrophy [8].
- **Cancer:** STRIPAK components are dysregulated in several malignancies; targeting the complex could have anti-tumor effects.

**Proteolysis-targeting chimeras (PROTACs):** The development of PROTACs that degrade STRN-ALK fusion proteins is theoretically feasible, leveraging the ALK kinase domain for selective recognition. However, no such agents have entered clinical development.

### 6.4 Gene Therapy and Genome Editing

The use of CRISPR-Cas9 to disrupt the *STRN* breakpoint region or to introduce therapeutic mutations is in preclinical stages. The primary challenge is the need for tumor-specific delivery, as systemic STRN knockout would be lethal.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 6801 | https://www.ncbi.nlm.nih.gov/gene/6801 |
| Ensembl | ENSG00000115808 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115808 |
| UniProt | O43815 | https://www.uniprot.org/uniprotkb/O43815 |
| RCSB PDB | (See Section 2) | https://www.rcsb.org/ |
| OMIM | 605056 | https://www.omim.org/entry/605056 |
| ClinVar | STRN | https://www.ncbi.nlm.nih.gov/clinvar/?term=STRN |
| COSMIC | STRN | https://cancer.sanger.ac.uk/cosmic |
| STRING | STRN (human) | https://string-db.org/ |
| BioGRID | 112345 | https://thebiogrid.org/ |
| GTEx | STRN | https://gtexportal.org/ |
| Human Protein Atlas | STRN | https://www.proteinatlas.org/ENSG00000115808-STRN |
| GeneCards | STRN | https://www.genecards.org/cgi-bin/carddisp.pl?gene=STRN |

**Gene Ontology (GO) Terms:**

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Calmodulin binding | GO:0005516 |
| Molecular Function | Protein phosphatase 2A binding | GO:0051721 |
| Molecular Function | Protein kinase binding | GO:0019901 |
| Biological Process | Regulation of protein phosphorylation | GO:0001932 |
| Biological Process | Hippo signaling | GO:0035329 |
| Biological Process | Response to aldosterone | GO:0036055 |
| Cellular Component | STRIPAK complex | GO:0071339 |
| Cellular Component | Caveola | GO:0005901 |
| Cellular Component | Cytoplasm | GO:0005737 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] "STRN Gene" - (2020). Definitions. URL: https://www.semanticscholar.org/paper/26f5b0503c7a758d760ff5aa09461ba9244e45fa

[2] Moqrich A, Mattei M, Bartoli M, Rakitina T, Baillat G, Monneron A, Castets F. "Cloning of human striatin cDNA (STRN), gene mapping to 2p22-p21, and preferential expression in brain." *Genomics*. 1998. URL: https://www.semanticscholar.org/paper/889595ae301d90adb02bb54165abce5e3ab6d475

[3] Zhang X, Yuan W, Luo R, Luan L, Huang J, Lu S, Sujie A, Hou Y. "Ciliated Muconodular Papillary Tumors of the Lung Harboring STRN::ALK Fusion: Case Report and Review of the Literature." *International Journal of Surgical Pathology*. 2024. URL: https://www.semanticscholar.org/paper/3b76a1f0031af45d0f717973ee6731bd77e1ece5

[4] Rosebush M, Smith MH, Cordell K, Callahan N, Zaid W, Gagan J, Bishop J. "Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males." *Head and Neck Pathology*. 2024. URL: https://www.semanticscholar.org/paper/a046dcc655029541da6667f2553ef766c0db4fa5

[5] Kusano H, Togashi Y, Akiba J, Moriya F, Baba K, Matsuzaki N, Yuba Y, Shiraishi Y, Kanamaru H, Kuroda N, Sakata S, Takeuchi K, Yano H. "Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene." *American Journal of Surgical Pathology*. 2016. URL: https://www.semanticscholar.org/paper/b0c141a3359df1b9bd05f4508e3e3dcdd301a7a3

[6] Pena-Burgos E, Suárez-González J, Hernández Muñoz L, Arregui Valles M, Asencio JM, Mora-Díaz R, Pozo-Kreilinger J. "STRN::NTRK3-fused neoplasm with 'monster cells' in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms." *Virchows Archiv*. 2026. URL: https://www.semanticscholar.org/paper/a76881a0b09fc65b94835725a7dd32820c741373

[7] Soliman RH, Shi C, Fisher KE, Yu H, El-dana F, Cao X, Liang L, Ying P, Zhang S. "Oncocytic Intraductal Carcinoma of the Parotid Gland with STRN::ALK Fusion." *Head and Neck Pathology*. 2026. URL: https://www.semanticscholar.org/paper/94f0eb6e8c5ef990dd70ad1fb74a36252448f3ee

[8] Lin R, Mallick A, Wang Z, Brown SA, Lu B, Jiang W. "Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy." *Diagnostic Pathology*. 2023. URL: https://www.semanticscholar